Trial Profile
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 02 Apr 2018 Status changed from active, no longer recruiting to completed.
- 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 10 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.